Ammar A, Rajerison R M, Roseau S, Bloch-Faure M, Butlen D
Laboratoire de Physiologie Cellulaire, Unité de Recherche Associée 219, Centre National de la Recherche Scientifique, Collège de France, Paris.
Am J Physiol. 1994 Nov;267(5 Pt 2):R1198-208. doi: 10.1152/ajpregu.1994.267.5.R1198.
Vasotocin receptors were investigated in glomeruli and nephron segments microdissected from collagenase-treated kidneys of Rana ridibunda, using [d(CH2)5Tyr(Me)2,Thr4,Orn8,125I-Tyr-NH2(9)]vasotocin (125I-OVTA) as a radioligand. Specific 125I-OVTA binding sites were found only in glomeruli and not in all tubule segments tested. Glomerular receptors exhibited the following stereospecificity for recognition of vasotocin analogues: Tyr-NH2(9)-LA-V1a > 125I-OVTA > arginine vasotocin (AVT) > or = [d(CH2)5Tyr-(Me)2]AVP > OVTA > or = [Phe2,Orn8]VT > oxytocin (OT) > or = [d(CH2)5-Sar7]AVP > desGly9[d(CH2)5Tyr(Et)2]VAVP > or = [d(CH2)5Tyr(Et)2]VAVP > AVP > [1-desamino-8-D-arginine]vasopressin (DDAVP) > [Thr4,Gly7]OT. In addition, vasotocin enhanced [3H]inositol phosphate production in sieved glomeruli labeled with myo-[3H]inositol; the rank order of structural vasotocin analogues for stimulation of phosphoinositidase C was [Phe2,Orn8]VT > AVT > OT > AVP > DDAVP, whereas [Thr4,Gly7]OT was almost inactive, and the rank order of antagonists for inhibition of hormone-induced enzyme activation was Tyr-NH2(9)-LA-V1a > [d(CH2)5Tyr(Me)2]AVP = OVTA > [d(CH2)5Sar7]AVP > [d(CH2)5Tyr(Et)2]VAVP > or = desGly9[d(CH2)5Tyr(Et)2]VAVP. Results indicate that the 125I-OVTA-labeled binding sites detected in frog glomeruli reveal the pharmacological properties of mammalian V1b-pituitary vasopressin receptors and might be physiological vasotocin receptors involved in phosphoinositidase C stimulation.
以[d(CH2)5Tyr(Me)2,Thr4,Orn8,125I-Tyr-NH2(9)]血管紧张素(125I-OVTA)作为放射性配体,对从食用蛙经胶原酶处理的肾脏中显微分离出的肾小球和肾单位节段中的血管紧张素受体进行了研究。仅在肾小球中发现了特异性的125I-OVTA结合位点,而在所测试的所有肾小管节段中均未发现。肾小球受体对血管紧张素类似物的识别表现出以下立体特异性:Tyr-NH2(9)-LA-V1a > 125I-OVTA > 精氨酸血管紧张素(AVT)> 或 = [d(CH2)5Tyr-(Me)2]AVP > OVTA > 或 = [Phe2,Orn8]VT > 催产素(OT)> 或 = [d(CH2)5-Sar7]AVP > desGly9[d(CH2)5Tyr(Et)2]VAVP > 或 = [d(CH2)5Tyr(Et)2]VAVP > AVP > [1-去氨基-8-D-精氨酸]血管加压素(DDAVP)> [Thr4,Gly7]OT。此外,血管紧张素增强了用肌醇-[3H]标记的筛状肾小球中[3H]肌醇磷酸的产生;刺激磷脂酶C的血管紧张素结构类似物的排名顺序为[Phe2,Orn8]VT > AVT > OT > AVP > DDAVP,而[Thr4,Gly7]OT几乎无活性,抑制激素诱导的酶激活的拮抗剂的排名顺序为Tyr-NH2(9)-LA-V1a > [d(CH2)5Tyr(Me)2]AVP = OVTA > [d(CH2)5Sar7]AVP > [d(CH2)5Tyr(Et)2]VAVP > 或 = desGly9[d(CH2)5Tyr(Et)2]VAVP。结果表明,在蛙肾小球中检测到的125I-OVTA标记的结合位点揭示了哺乳动物V1b-垂体血管加压素受体的药理学特性,并且可能是参与磷脂酶C刺激的生理性血管紧张素受体。